drugset / Trial / NCT05895877

Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic Constipation

NCT05895877

Phase 3 Unknown 351 enrolled Synmosa Biopharma Corp.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of Goofice® in patients with chronic constipation.

Timeline

Start
2021-12-21
Primary completion
2023-09-30
Completion
2023-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Elobixibat Small molecule 5 mg
Comparator Elobixibat Small molecule 10 mg
Comparator Elobixibat Small molecule 15 mg

Indications